🧠

Neuroscience

Drug development for neurological and psychiatric disorders including Alzheimer's, Parkinson's, depression, and rare neurological conditions.

Companies

Pipeline Drugs

474

Key People

624

Neuroscience Pipeline (474 drugs)

Phase 3: 65Pre-clinical: 39Phase 2: 33Preclinical: 32Commercial: 32Approved: 28Phase 1: 18Research: 12Discovery: 12Phase 1/2: 11N/A: 9Research Tool: 8Phase 2/3: 7Service: 7Phase III: 7Phase 2a: 6Development: 6Not Disclosed: 6Phase 2b: 4Marketed: 4Commercial Model: 4Regulatory Review: 4Phase II: 3Discovery/Preclinical: 3Research/Preclinical Tools: 3Research-Use Only: 3Approved / Lifecycle: 3Phase 2b/3: 2Approved/Under Review: 2Preclinical/Phase 1: 2Clinical (China & US): 2R&D: 2Feasibility: 2Launched: 2Commercialization: 2Research-Use-Only: 2Pre-clinical / Phase 1: 2NDA Submitted: 2Research/Assay Development: 2Phase I: 2Commercial/Development: 2Clinical research: 2Pre‑clinical: 2Approved / Phase III: 2Phase IIb: 1Pipeline: 1Under Regulatory Review: 1Filed: 1Early Commercialization: 1Registry: 1Clinical (pediatric trials): 1FDA Cleared: 1Advanced Development: 1Early Discovery: 1Preclinical Research: 1Preclinical/Translational: 1Clinical Research: 1All Phases: 1Approved (India): 1Pivotal Trial: 1Investigational: 1Discovery/Pre-clinical: 1Pre-clinical / IND-enabling: 1N/A (Platform): 1N/A (Diagnostic Tool): 1N/A (Research Tool): 1Service Offering: 1Approved/Commercial: 1Research/Preclinical: 1Pre-clinical/Formulation: 1Pivotal: 1Phase not specified (Data presented): 1Open-Label Extension: 1Acquisition announced: 1Pre-commercial: 1Platform Development: 1Lead Optimisation: 1Pre-clinical/Development: 1Tool Development: 1Business Development: 1Research/Concept: 1Pre-clinical/Clinical: 1Commercial/Research: 1N/A (Device-enabled trial): 1Various (Pre-clinical to Phase 3): 1Research/Validation: 1Registration/Clinical: 1Pivotal Trial Completed: 1Post-Market Study: 1Pre-market Clinical Research: 1Regulatory Review (NMPA Green Path): 1CE Mark Obtained; NMPA Green Path: 1NMPA Approved: 1Validated Instrument: 1Pre-validated/Validation Ongoing: 1Post-Market: 1Approved (via voluntary license): 1Market: 1Phase III / Marketed: 1Phase I/II: 1Launched/Phase 3: 1Pre-registration: 1Phase 3 / Registration: 1Preclinical to Phase 2: 1CE Mark / FDA Clearance (Ongoing): 1PMA Under Review: 1Clinical Trials: 1Clinical Investigation: 1Marketed / Late-stage Study: 1Preclinical / Phase 1: 1Phase 1/2 (Inferred): 1Phase 1 (Inferred): 1BLA Submitted: 1Phase I to Phase III: 1sNDA Review: 1

Drug	Company	Indication	Phase	Status
DB102 (Enzastaurin)	Denovo Biopharma	Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 3	Active
DB103 (Pomaglumetad)	Denovo Biopharma	Schizophrenia	Phase 2b/3	Active
DB104 (Liafensine)	Denovo Biopharma	Treatment-Resistant Depression	Phase 2b	Active
DB107 (Toca 511 & Toca FC)	Denovo Biopharma	Recurrent High-Grade Glioma	Phase 2/3	Active
Presendin™ (Exenatide)	Invex Therapeutics	Idiopathic Intracranial Hypertension (IIH)	Phase 2/3	Active
SCI-110	SciSparc	Tourette Syndrome	Phase IIb	Active
SCI-160	SciSparc	Chronic Pain	Preclinical	Active
SCI-210	SciSparc	Autism Spectrum Disorder (ASD)	Phase II	Active
IQool™ System	BrainCool	Post-Cardiac Arrest	Marketed	Commercial
ZZ6398	Zhongze Therapeutics	Schizophrenia	Phase 1/2	Active
ZURZUVAE (zuranolone)	Sage Therapeutics	Postpartum Depression	Approved	Commercial
SAGE-718	Sage Therapeutics	Cognitive Impairment - Huntington's Disease	Phase 2	Active
SAGE-324	Sage Therapeutics	Essential Tremor	Phase 2	Active
SAGE-689	Sage Therapeutics	Not Disclosed	Phase 1	Paused
SAGE-904	Sage Therapeutics	Not Disclosed	Preclinical	Research
ICOTYDE (icotrokinra)	johnson-and-johnson-innovative-medicine	Moderate-to-Severe Plaque Psoriasis	Approved	Approved (FDA Mar 2026)
TECVAYLI + DARZALEX FASPRO	johnson-and-johnson-innovative-medicine	Relapsed/Refractory Multiple Myeloma	Approved	Approved (FDA Mar 2026)
Nipocalimab	johnson-and-johnson-innovative-medicine	Systemic Lupus Erythematosus (SLE)	Phase 3	Active (Fast Track Designation)
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Alzheimer's Disease	Pipeline	Active
Dupixent (dupilumab)	Regeneron	Chronic Obstructive Pulmonary Disease (COPD)	Phase 3	Active
Odronextamab	Regeneron	Relapsed/Refractory Follicular Lymphoma & DLBCL	Phase 3	Active (BLA under review)
Pozelimab	Regeneron	Complement 3 Glomerulopathy (C3G)	Phase 3	Active
Garetosmab	Regeneron	Fibrodysplasia Ossificans Progressiva (FOP)	Phase 3	Active
Linvoseltamab	Regeneron	Relapsed/Refractory Multiple Myeloma	Phase 3	Active
Fianlimab + Cemiplimab	Regeneron	Advanced Melanoma (1L adjuvant)	Phase 3	Active
REGN1908-1909 (Fel d 1 mAb)	Regeneron	Cat Allergy	Phase 3	Active
VEGF C-D	Regeneron	Neovascular Age-Related Macular Degeneration (nAMD)	Phase 2/3	Active
TAK-755 (rADAMTS13)	Takeda	Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	Phase 3	Active
TAK-861	Takeda	Narcolepsy Type 1 (NT1)	Phase 3	Active
TAK-279 (NDI-034858)	Takeda	Moderate-to-Severe Plaque Psoriasis	Phase 3	Active
Soticlestat (TAK-935)	Takeda	Dravet Syndrome, Lennox-Gastaut Syndrome	Phase 3	Active
TAK-676 + pembrolizumab	Takeda	Solid Tumors	Phase 1/2	Active
TAK-500	Takeda	Solid Tumors	Phase 1/2	Active
TAK-186 (Goreisan)	Takeda	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Phase 2	Active
TAK-671	Takeda	Acute Pancreatitis	Phase 2	Active
FOL-005	Takeda	Androgenetic Alopecia	Phase 2a	Active
TAK-101	Takeda	Celiac Disease	Phase 2	Active
TAK-062	Takeda	Celiac Disease	Phase 2	Active
TAK-954	Takeda	Pediatric Gastrointestinal Motility Disorders	Phase 2	Active
Biosimilar to Xgeva® (denosumab)	Teva	Oncology (bone metastases)	Approved/Under Review	Launched in EU, under review in US
Biosimilar to Prolia® (denosumab)	Teva	Osteoporosis	Approved/Under Review	Launched in EU, under review in US
Biosimilar to Simponi® (golimumab)	Teva	Inflammatory Diseases	Under Regulatory Review	In collaboration with Alvotech for U.S.
Biosimilar to Xolair® (omalizumab)	Teva	Asthma, Chronic Spontaneous Urticaria	Filed	Dual filing acceptance announced
TEV-'574 (or similar)	Teva	Ulcerative Colitis, Crohn’s Disease	Phase 3	Active
Asthma Candidate	Teva	Asthma	Phase 3	Active
Schizophrenia Candidate	Teva	Schizophrenia	Phase 3	Active
MSA Candidate	Teva	Multiple System Atrophy	Phase 2	Active
Vitiligo Candidate	Teva	Vitiligo	Phase 2	Active
Attenukine Oncology Candidate	Teva	Oncology	Phase 1	Active
Immuno-oncology Candidate	Teva	Malignant Melanoma	Preclinical/Phase 1	Active